Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Letter to the Editor
  • Published:

A G polymorphism in the CRBN gene acts as a biomarker of response to treatment with lenalidomide in low/int-1 risk MDS without del(5q)

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

References

  1. Ito T, Ando H, Suzuki T, Ogura T, Hotta K, Imamura Y et al. Identification of a primary target of thalidomide teratogenicity. Science 2010; 327: 1345–1350.

    Article  CAS  PubMed  Google Scholar 

  2. Lopez-Girona A, Mendy D, Ito T, Miller K, Gandhi AK, Kang J et al. Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide. Leukemia 2012; 26: 2326–2335.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Andhavarapu S, Roy V . Immunomodulatory drugs in multiple myeloma. Expert Rev Hematol 2013; 6: 69–82.

    Article  CAS  PubMed  Google Scholar 

  4. Adès L, Fenaux P . Immunomodulating drugs in myelodysplastic syndromes. Am Soc Hematol Educ Program 2011; 2011: 556–560.

    Article  Google Scholar 

  5. List A, Dewald G, Bennett J, Giagounidis A, Raza A, Feldman E et al. Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. N Engl J Med 2006; 355: 1456–1465.

    Article  CAS  PubMed  Google Scholar 

  6. Raza A, Reeves JA, Feldman EJ, Dewald GW, Bennett JM, Deeg HJ et al. Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1 risk myelodysplastic syndromes with karyotypes other than deletion 5q. Blood 2008; 111: 86–93.

    Article  CAS  PubMed  Google Scholar 

  7. Zhu YX, Braggio E, Shi CX, Bruins LA, Schmidt JE, Van Wier S et al. Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide. Blood 2011; 118: 4771–4779.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Broyl A, Kuiper R, van Duin M, van der Holt B, El Jarari L, Bertsch U et al. High cereblon expression is associated with better survival in patients with newly diagnosed multiple myeloma treated with thalidomide maintenance. Blood 2013; 121: 624–627.

    Article  CAS  PubMed  Google Scholar 

  9. Raza A, Meyer P, Dutt D, Zorat F, Lisak L, Nascimben F et al. Thalidomide produces transfusion independence in long-standing refractory anemias of patients with myelodysplastic syndromes. Blood 2001; 98: 958–965.

    Article  CAS  PubMed  Google Scholar 

  10. Fenaux P, Giagounidis A, Selleslag D, Beyne-Rauzy O, Mufti G, Mittelman M et al. A randomized phase 3 study of lenalidomide versus placebo in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with del5q. Blood 2011; 118: 3765–3776.

    Article  CAS  PubMed  Google Scholar 

  11. Komrokji RS, Lancet JE, Swern AS, Chen N, Paleveda J, Lush R et al. Combined treatment with lenalidomide and epoetin alfa in lower-risk patients with myelodysplastic syndrome. Blood 2012; 120: 3419–3424.

    Article  CAS  PubMed  Google Scholar 

  12. Gandhi AK, Avet-Loiseau H, Waldman M, Thakurta A, Aukerman SL, Chen G et al. Detection and quantification of cereblon protein and mRNA in multiple myeloma cell lines and primary CD138+multiple myeloma cells. ASH 2012; (abstract #4043).

  13. Ebert BL, Galili N, Tamayo P, Bosco J, Mak R, Pretz J et al. An erythroid differentiation signature predicts response to lenalidomide in myelodysplastic syndrome. PLoS Med 2008; 5: e35.

    Article  PubMed  PubMed Central  Google Scholar 

  14. Sugimoto Y, Sekeres MA, Makishima H, Traina F, Visconte V, Jankowska A et al. Cytogenetic and molecular predictors of response in patients with myeloid malignancies without del[5q] treated with lenalidomide. J Hematol Oncol 2012; 5: 4.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Wei S, Chen X, McGraw K, Zhang L, Komrokji R, Clark J et al. Lenalidomide promotes p53 degradation by inhibiting MDM2 auto-ubiquitination in myelodysplastic syndrome with chromosome 5q deletion. Oncogene 2013; 32: 1110–1120.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

This work was supported by the Direction régionale de la recherche clinique Assistance-Publique Hôpitaux de Paris (PHRC MDS-04). We thank Raphael Petit and Rosa Sapena for collecting clinical data, and Morgane Bourmaud and Audrey Gauthier for technical assistance.

Authors contributions

VS, SK, VC and CL performed the experiments; AR performed all statistical analysis; LA, VS, SP, AT, PF, FD provided samples; PF, MF, OK wrote the paper; OK conceived and was responsible for the study design.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to O Kosmider.

Ethics declarations

Competing interests

VS is consultant for Celgene, Janssen and Novartis. PF is consultant for Celgene, Ortho Biotech, Roche, Novartis, Cephalon, Epicept, Amgen, and Merck. FD is consultant for Novartis. MF is consultant for Celgene

Rights and permissions

Reprints and permissions

About this article

Cite this article

Sardnal, V., Rouquette, A., Kaltenbach, S. et al. A G polymorphism in the CRBN gene acts as a biomarker of response to treatment with lenalidomide in low/int-1 risk MDS without del(5q). Leukemia 27, 1610–1613 (2013). https://doi.org/10.1038/leu.2013.59

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/leu.2013.59

This article is cited by

Search

Quick links